Rhizome AI

Executive Summary

Rhizome AI is a US-based artificial intelligence startup that applies diffusion-based generative models to design novel small-molecule therapeutics and biologics. Its platform integrates large-scale language model reasoning with molecular physics, enabling automated early-stage drug discovery workflows. The company focuses on oncology and immunology, aiming to accelerate hit-to-lead cycles and reduce the cost and time required to bring new therapies to clinical trials. Founded in 2020, Rhizome AI operates as a platform-stage private company, leveraging its proprietary technology to partner with pharmaceutical companies seeking to enhance their research pipelines. Rhizome AI's value proposition lies in its ability to combine generative AI with molecular physics to rapidly explore chemical space and identify promising drug candidates. By automating the hit-to-lead process, the platform offers significant efficiency gains over traditional discovery methods. The company's business model centers on collaborations with pharma partners, who benefit from faster and cheaper lead generation. While Rhizome AI has yet to disclose funding details or commercial partnerships, its technology addresses a critical bottleneck in drug development. If successful, the platform could substantially improve the productivity of early-stage drug discovery, particularly in high-unmet-need areas like oncology and immunology.

Upcoming Catalysts (preview)

• Q3 2026Announcement of first major pharma partnership60% success
• Q2 2026Publication of preclinical validation data in a peer-reviewed journal70% success
• Q4 2026Series A funding round closure50% success